Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxular Sets Out Eye Disease Plans Armed With $37m

Forbion Leads Financing

Executive Summary

The fresh cash injection will fund Phase II studies evaluating the UK firm's 12-month treatment for diabetic macular edema.

You may also be interested in...



Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals

Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds. 

Roche’s Ophthalmic Bi-Specific Faricimab Still A DME Contender

Initial data show non-inferiority to Eylea in diabetic macular edema with reduced frequency dosing but not superiority. Even so, market dynamics suggest it could still carve out blockbuster sales.

FDA Perturbed By Provention's Teplizumab Type 1 Diabetes Drug

The US regulator is worried about deficiencies in the submission for Provention Bio’s high-profile therapy teplizumab for the prevention of type 1 diabetes that could significantly delay its review.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel